What Happened to Hapvida (HAPV3), According to Squadra?
Asset manager Squadra admitted in its latest semi-annual letter to investors that its investment in Hapvida (HAPV3) shares was the biggest mistake in its history. Widely known in the financial markets for its technical rigor and for exposing accounting inconsistencies at major companies in the past, the firm revealed that it underestimated the operational challenges and value destruction stemming from the merger between Hapvida and NotreDame Intermédica (GNDI).
According to the firm, the investment thesis—which looked solid on paper, based on creating a national healthcare giant with a verticalized model and massive economies of scale—ran into an operational reality far more complex and hostile than projected. The integration process between the two companies generated severe friction, while the post-pandemic macroeconomic and sector environment eroded the margins that previously justified the stock's high valuation multiples.
By publicly owning up to the mistake, Squadra adopted a level of transparency rarely seen in the Brazilian capital markets, especially given that the thesis consumed a significant portion of its assets under management over recent years. The admission serves as a stark warning to retail investors about the risks of carrying high-growth theses that rely on massive mergers in capital- and regulation-intensive sectors.
Why Did the HAPV3 Thesis Go So Wrong for the Firm?
The core of the miscalculation, according to Squadra, lay in the flawed integration between Hapvida and NotreDame Intermédica. The merger, designed to capture billions in synergies and consolidate the low-cost healthcare market in Brazil, ultimately revealed corporate cultures that were difficult to unify and incompatible operating systems, which delayed efficiency gains and drove up transition costs.
Beyond internal execution issues, the supplemental healthcare sector faced a perfect storm in the years following the business combination. Medical inflation climbed persistently, driven by rising costs for medical supplies and drugs, alongside the resumption of elective procedures that had been deferred during the pandemic. This dynamic directly pressured the company's loss ratio—the proportion of premium revenue spent on patient care.
The Achilles' Heel of Verticalization: The model of proprietary hospitals (verticalization), which has historically been Hapvida's main competitive advantage for keeping costs down, showed signs of saturation and inefficiency when expanded into more complex metropolitan areas where NotreDame Intermédica historically operated.
Squadra also found that Hapvida's pricing power was outpaced by the deterioration of the population's average income and the tight budgets of corporate clients. In health plans targeting lower-middle-income brackets, any attempt to raise prices above inflation results in mass cancellations (churn), limiting the company's pricing power precisely when it needed to rebuild operating margins.
What Is Squadra Doing With Its Portfolio Now?
After acknowledging the failure of the Hapvida thesis, Squadra sharply reduced its exposure to the stock, stopping the capital loss and redirecting its resources toward new opportunities on the Brazilian exchange. The firm indicated it is focusing on assets that offer more predictable cash flows, stronger barriers to entry, and, above all, do not depend on major merger and acquisition (M&A) events to unlock value.
Although the letter notes that the firm identified promising opportunities in four other local stocks, Squadra chose to keep its strategic focus on recycling its portfolio without carrying a bias toward trying to recoup losses in the same asset that caused them. This portfolio discipline is one of the most important concepts retail investors can take away from this episode: money lost on a stock does not necessarily need to be won back on that same stock.
The firm's portfolio rotation reflects a broader push toward quality over high-growth stories at any cost. In an environment of structurally higher interest rates in Brazil, companies with controlled debt and a proven ability to generate short-term free cash flow take priority in major fund allocations.
Is It Worth Investing in Hapvida (HAPV3) After the Firm's Verdict?
The decision to invest in or hold Hapvida (HAPV3) requires retail investors to weigh Squadra's pessimism against the stock's current price, which already carries a steep discount relative to historical highs. The financial markets tend to heavily punish companies undergoing restructuring, which can create mispricings for investors with a very long-term horizon.
On one hand, the structural challenges pointed out by the firm are real and will not disappear overnight. Regulation by the National Supplementary Health Agency (ANS) remains strict, the sector's loss ratio takes quarters to converge back to historical averages, and GNDI's full integration continues to demand management attention. Investors buying HAPV3 today must understand that they are acquiring a turnaround thesis, rather than a story of linear and predictable growth.
The Verdict for Investors
If one of the most thorough investment firms in the country has capitulated in the face of Hapvida's complexity, individual investors should exercise extra caution. Maintaining a small, controlled position may only make sense for those who believe in a marginal recovery of operating margins over the coming years. For defensive investors seeking dividends or lower volatility, the supplemental healthcare sector currently presents more uncertainties than attractive risk premiums.
The takeaway from Squadra's move is that even the most qualified professionals in the market are vulnerable to long-term valuation errors. The difference between success and failure for everyday investors lies in the ability to recognize these mistakes quickly, limit losses, and diversify portfolios so that no single thesis can compromise their financial future.
